By Erica Teichert ( December 7, 2012, 7:30 PM EST) -- Mylan Pharmaceuticals Inc. told a Washington federal judge on Friday that it should be allowed to start marketing a generic version of its hypertension drug valsartan, alleging Ranbaxy Laboratories Ltd. has forfeited its exclusivity rights by not actively pursuing U.S. Food and Drug Administration approval....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.